Masimo Corp. (MASI) CEO Joe E. Kiani Sells 2,200 Shares
Masimo Corp. (NASDAQ:MASI) CEO Joe E. Kiani sold 2,200 shares of the business’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $60.00, for a total value of $132,000.00. Following the sale, the chief executive officer now owns 121,441 shares in the company, valued at $7,286,460. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Masimo Corp. (NASDAQ:MASI) opened at 59.67 on Thursday. The company has a 50-day moving average price of $59.01 and a 200 day moving average price of $51.27. The firm has a market capitalization of $2.94 billion, a price-to-earnings ratio of 31.29 and a beta of 0.70. Masimo Corp. has a 1-year low of $33.03 and a 1-year high of $60.52.
Masimo Corp. (NASDAQ:MASI) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.16. The firm earned $172.64 million during the quarter, compared to analyst estimates of $166.02 million. Masimo Corp. had a return on equity of 29.07% and a net margin of 15.40%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the company posted $0.36 EPS. Equities analysts anticipate that Masimo Corp. will post $2.02 earnings per share for the current year.
A number of equities analysts have recently weighed in on MASI shares. Zacks Investment Research cut Masimo Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Wedbush reissued an “outperform” rating and issued a $63.00 price target (up from $60.00) on shares of Masimo Corp. in a report on Thursday, August 4th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $55.00 price target (up from $52.00) on shares of Masimo Corp. in a report on Friday, August 5th. Finally, BTIG Research reissued a “hold” rating on shares of Masimo Corp. in a report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $52.60.
A number of institutional investors have recently modified their holdings of MASI. PineBridge Investments L.P. raised its position in shares of Masimo Corp. by 2.7% in the second quarter. PineBridge Investments L.P. now owns 5,591 shares of the company’s stock worth $293,000 after buying an additional 149 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Masimo Corp. by 0.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 56,685 shares of the company’s stock worth $2,372,000 after buying an additional 400 shares during the last quarter. Teachers Advisors Inc. raised its position in shares of Masimo Corp. by 0.7% in the second quarter. Teachers Advisors Inc. now owns 65,736 shares of the company’s stock worth $3,452,000 after buying an additional 460 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Masimo Corp. by 1.6% in the second quarter. UBS Asset Management Americas Inc. now owns 28,855 shares of the company’s stock worth $1,515,000 after buying an additional 467 shares during the last quarter. Finally, UBS Group AG raised its position in shares of Masimo Corp. by 3.6% in the first quarter. UBS Group AG now owns 19,177 shares of the company’s stock worth $802,000 after buying an additional 663 shares during the last quarter. 79.88% of the stock is owned by hedge funds and other institutional investors.
Masimo Corp. Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Stock Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related stocks with our FREE daily email newsletter.